Google Custom Search

Psychiatric Illness and Substance Use in Veterans with and without Hepatitis C

The presence of psychiatric conditions and substance (alcohol and illicit drug) use may affect decisions about whether to treat chronic hepatitis C. Some clinicians believe individuals with these comorbidities may have difficulty achieving good adherence, and some studies suggest they may be more likely to experience psychiatric side effects of interferon-based therapy, including depression.

As reported in the December 2007 Journal of Viral Hepatitis, researchers conducted a study to determine the prevalence of psychiatric conditions and substance abuse among 12,926 veterans with hepatitis C treated at a Veterans Administration (VA) medical facility and an equal number of HCV-uninfected control subjects

Demographic and comorbidity data were retrieved from the VA National Patient Care Database using ICD-9 codes. Logistic regression was used to determine the odds of comorbid conditions in the HCV-infected patients. HCV-uninfected control subjects were matched by age, race/ethnicity, and sex.

Results

The HCV-infected patients had a higher prevalence of diabetes, anemia, hypertension, chronic obstructive pulmonary disease (COPD) or asthma, liver cirrhosis, hepatitis B, and cancer than the uninfected control subjects.

By contrast, the HCV patients had a lower prevalence of coronary artery disease and stroke.

The prevalence of all psychiatric comorbidities and substance abuse was higher in the HCV-infected patients than the control subjects.

After adjusting for alcohol and drug abuse and dependence, however, the odds of psychiatric illness were not higher for the HCV-infected individuals.

Conclusion

In conclusion, the authors wrote, "The prevalence and patterns of comorbidities in HCV-infected veterans are different from those in HCV-uninfected controls."

"The association between HCV and psychiatric diagnoses is at least partly attributable to alcohol and drug abuse and dependence," they added. "These factors should be taken into account when evaluating patients for treatment and designing new intervention strategies."

University of Pittsburgh School of Medicine, Pittsburgh, PA; VA Pittsburgh Healthcare System, Pittsburgh, PA; Center for Health Equity Research and Promotion, Pittsburgh, PA.

01/08/08

Reference
AA Butt, UA Khan, KA McGinnis. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. Journal of Viral Hepatitis 14(12): 890-896. December 2007.

Hepatitis C Main Section
FDA-approved Treatments for HCV

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Monotherapies
Intron A
Roferon

Infergen

Pegasys
PEG-Intron
FDA-approved
Combination Therapies
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin